Halted trial tests new shot against silent liver virus
NCT ID NCT02797522
Summary
This was an early-stage study to test the safety and effects of a new drug called ARC-521 for people with chronic Hepatitis B. It involved 47 healthy volunteers and patients to see how their bodies handled different doses and if the drug could reduce the virus. The main goal was to check for side effects and see how the drug moved through the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Grafton, Auckland, 1011, New Zealand
Conditions
Explore the condition pages connected to this study.